Sandbox endocarditis2: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:


{| class="wikitable" style="margin: 1em auto 1em auto"
==Medical Therapy==
|+
! Epidemiological features || Common Microorganism(s)
|-
| <center>'''Injection drug use'''</center>||
*S aureus, including community-acquired
*oxacillin-resistant strains
*Coagulase-negative staphylococci
*β-Hemolytic streptococci
*Fungi
*Aerobic Gram-negative bacilli, including
:*Pseudomonas aeruginosa
|-
| <center>'''Indwelling cardiovascular medical devices'''</center> ||
*S aureus
*Coagulase-negative staphylococci
*Fungi
*Aerobic Gram-negative bacilli
*Corynebacterium sp
|-
| <center>'''Genitourinary disorders'''</center>


<center>'''Genitourinary infection'''</center>
===Pharmacotherapy===


<center>'''Genitourinary manipulation'''</center>
====Community-Acquired Meningitis====


<center>'''pregnancy'''</center>


<center>'''Delivery'''</center>


<center>'''Abortion'''</center>
{|
||
*Enterococcus sp
*Group B streptococci (S agalactiae)
*Listeria monocytogenes
*Aerobic Gram-negative bacilli
*Neisseria gonorrhoeae
|-
|-
| <center>'''Chronic skin disorders''' </center>||
| valign=top |
S aureus
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
β-Hemolytic streptococci
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml}}''
|-
|-
| <center>'''Poor dental health, dental procedures''' </center>||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
*Viridans group streptococci
*“Nutritionally variant streptococci”
*Abiotrophia defectiva
*Granulicatella sp
*Gemella sp
*HACEK organisms
|-
|-
| <center>'''Alcoholism, cirrhosis''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''Adult''':'''''[[Penicillin G potassium|Aqueous crystalline penicillin G sodium]] 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks '''''<BR> '''Pediatrics''':'''''[[Penicillin G potassium|Aqueous crystalline penicillin G sodium]] 300 000 U/24 h IV in 4–6 equally divided doses X 4 Wks '''''<BR>''OR'' <BR> ▸'''Adult''':'''''[[Ceftriaxone]] 2 g/24 h IV/IM in 1 dose''''' <BR> ▸'''Pediatrics''':'''''[[Ceftriaxone]] 100 mg/kg per 24 h IV/IM in 1 dose'''''
*Bartonella sp
*Aeromonas sp
*Listeria sp
*S pneumoniae
*β-Hemolytic streptococci
|-
|-
| <center>'''Burn patients''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
*S aureus
*Aerobic Gram-negative bacilli, including
:*Pseudomonas aeruginosa
*Fungi
|-
|-
|  <center>'''Diabetes mellitus''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''Adult''':'''''[[Gentamicin]] 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks '''''<BR> '''Pediatrics''': '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses X 2 Wks'''''
*S aureus
*β-Hemolytic streptococci
*S pneumoniae
|-
|-
| <center>'''Early (1 y) prosthetic valve placement''' </center>||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Relatively Penicillin-Resistant Streptococci, MIC > 0.5 µg/ml, consider Enterococcal regimen}}''
*Coagulase-negative staphylococci
*S aureus
*Aerobic Gram-negative bacilli
*Fungi
*Corynebacterium sp
*Legionella sp
|-
|-
| <center>'''Late (>1 y) prosthetic valve placement''' </center>|| Coagulase-negative staphylococci
| style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
*S aureus
*Viridans group streptococci
*Enterococcus species
*Fungi
*Corynebacterium sp
|-
|-
| <center>'''Dog–cat exposure''' </center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''Adult''':'''''[[Penicillin G potassium|Aqueous crystalline penicillin G sodium]] 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks '''''
*Bartonella sp
*Pasteurella sp
*Capnocytophaga sp
|-
|-
| <center>'''Contact with contaminated milk'''</center>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
<center>'''Contact with infected farm animals'''</center>
||
*Brucella sp
*Coxiella burnetii
*Erysipelothrix sp
|-
|-
| <center>'''Homeless, body lice'''</center>|| *Bartonella sp
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''Adult''':'''''[[Gentamicin]] 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks  '''''
|-
|-
| <center>'''AIDS'''</center> ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Unable to tolerate [[Penicillin G potassium|Aqueous crystalline penicillin G sodium]] or [[Ceftriaxone]] }}''
*Salmonella sp
*S pneumoniae
*S aureus
|-
|-
| <center>'''Pneumonia, meningitis'''</center>||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
*S pneumoniae
|-
|-
| <center>'''Solid organ transplant'''</center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''Adult''': '''''[[Vancomycin]] 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low  '''''
*S aureus
*Aspergillus fumigatus
*Enterococcus sp
*Candida sp
|-
|-
| <center>'''Gastrointestinal lesions'''</center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''Pediatrics''': '''''[[Vancomycin]] 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks '''''
*S bovis
*Enterococcus sp
*Clostridium septicum
|-
|-
|}
|}
|}




==Empirical Antibiotic Therapy==


*Although antibiotic therapy for subacute disease can be delayed till the result of blood culture, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.  
{|
 
|-
*Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.
| valign=top |
 
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
*Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Newborn, Age <1 Week}}''
 
|-
{| class="wikitable" style="margin: 1em auto 1em auto"
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|+
|-
! Regimen || Dosage and Route || Duration(weeks)
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Newborn, Age 1—4 Weeks}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Infant and Children}}''<sup>†</sup>
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225—300 mg/kg/day IV q6–8h''''' <BR>''OR''<BR> ▸'''''[[Ceftriaxone]] 80—100 mg/kg/day IV q12–24h''''' <BR> <BR> <BR> <BR>
|-
|}
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
|-
|-
| ||'''''<u>Native valve</u>'''''||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| '''[[Ampicillin sulbactam]]'''||12 g per 24 h IV in 4 equally divided doses||4–6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
 
|-
|-
| || '''''plus''''' ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}''
|-
|-
| '''[[Gentamicin|Gentamicin sulfate]]'''|| 3 mg per kg per 24 h IV/IM in 3 equally divided doses||4–6 weeks
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| || '''or''' ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
|-
|-
| '''[[Vancomycin]]'''||30 mg per kg per 24 h IV in 2 equally divided doses||4–6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| || '''''plus''''' ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Ampicillin]] 2 g IV q4h'''''
|-
|-
| '''[[Gentamicin|Gentamicin sulfate]]'''||3 mg per kg per 24 h IV/IM in 3 equally divided doses||4–6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| || '''''plus''''' ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]]2 g IV q8h'''''
|-
|-
| '''[[Ciprofloxacin]]'''||1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally divided doses||4–6 weeks
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}''
|-
|-
| ||→'''Pediatric dose''':
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
*'''[[Ampicillin sulbactam]]''' 300 mg per kg per 24 h IV in 4–6 equally divided doses
*'''[[Gentamicin]]''' 3 mg per kg per 24 h IV/IM in 3 equally divided doses
*'''[[Vancomycin]]''' 40 mg per kg per 24 h in 2 or 3 equally divided doses
*'''[[Ciprofloxacin]]''' 20–30 mg per kg per 24 h IV/PO in 2 equally divided doses
||
|-
|-
| ||'''''<u>Prosthetic valve (early, ≤ 1y, , mostly Oxacillin resistent)</u>''''' ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h'''''
|-
|-
| '''[[Vancomycin]]'''||30 mg per kg per 24 h IV in 2 equally divided doses||6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| ||'''''plus'''''||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]  8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
|}
|}
 
<sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]''is also suspected.
 
<SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal  | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. |title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 380 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref>
 
====Empiric Treatment====
* Do not wait for the results of the [[CT scan]] and the [[lumbar puncture]]; empiric treatment should be started as soon as possible.
* Blood cultures should be drawn before starting the [[antibiotic]] therapy, and then the antibiotic treatment should be changed once the blood culture results are out.
 
* Empiric antibiotic treatment should be started within 30 minutes after the patient presentation.
* In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days.
** The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment.
 
{|
|-
|-
| '''[[Gentamicin|Gentamicin sulfate]]'''||3 mg per kg per 24 h IV/IM in 3 equally divided doses||2 weeks
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age <1 Week}}''
|-
|-
| ||'''''plus'''''||
 
 
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
|'''[[Cefepime]]'''||6 g per 24 h IV in 3 equally divided doses||6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
|-
| ||'''''plus'''''||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| '''[[Rifampin]]'''||900 mg per 24 h PO/IV in 3 equally divided doses||6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h'''''
|-
|-
| ||→'''Pediatric dose''':
 
*'''[[Vancomycin]]''' 40 mg per kg per 24 h IV in 2 or 3equally divided doses
 
*'''[[Gentamicin]]''' 3 mg per kg per 24 h IV/IM in 3 equally divided doses
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
*'''[[Cefepime]]''' 150 mg per kg per 24 h IV in 3 equally divided doses
*'''[[Rifampin]]''' 20 mg per kg per 24 h PO/IV in 3 equally divided doses
||
|-
|-
| ||'''''<u>Prosthetic valve (late—greater than 1 y, mostly Oxacillin sensitive)</u>'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
'''Same regimens as listed above for native valve endocarditis'''
||
|-
|-
| ||'''''<u>Suspected Bartonella, culture negative</u>''''' ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
|'''[[Ceftriaxone sodium]]'''||2 g per 24 h IV/IM in 1 dose||6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
|-
|-
| ||'''''plus'''''||
|}
 
 
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age <1 Week}}''
|-
|-
| '''[[Gentamicin|Gentamicin sulfate]]'''||3 mg per kg per 24 h IV/IM in 3 equally divided doses||2 weeks
 
 
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| ||'''''with/without'''''||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
|-
| '''[[Doxycycline]]'''||200 mg per kg per 24 h IV/PO in 2 equally divided doses||6 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| ||'''''<u>Documented Bartonella, culture positive</u>'''''||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h'''''
|-
|-
| '''[[Doxycycline]]'''||200 mg per 24 h IV or PO in 2 equally divided doses||6 weeks
 
 
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| ||'''''plus'''''||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
|-
|-
| '''[[Gentamicin|Gentamicin sulfate]]'''||3 mg per kg per 24 h IV/IM in 3 equally divided doses||2 weeks
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| ||→'''Pediatric dose''':
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
*'''[[Ceftriaxone]]''' 100 mg per kg per 24 h IV/IM once daily
*'''[[Gentamicin]]''' 3 mg per kg per 24 h IV/IM in 3 equally divided doses
*'''[[Doxycycline]]''' 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses
*'''[[Rifampin]]''' 20 mg per kg per 24 h PO/IV in 2 equally divided doses
||
|-
|-
|}
|}
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}''
|-




! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
|-


{| class="wikitable" style="margin: 1em auto 1em auto"
 
|+
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! Epidemiological features || Common Microorganism(s)
|-
|-
| <center>'''Injection drug use'''</center>||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
*S aureus, including community-acquired
*oxacillin-resistant strains
*Coagulase-negative staphylococci
*β-Hemolytic streptococci
*Fungi
*Aerobic Gram-negative bacilli, including
:*Pseudomonas aeruginosa
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
|-
|}
|}
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—23 Months}}''
|-




! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
|-




! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
|-




|}
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}''
|-




==Treatment Based Upon Infectious Agent<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F.,  Levison Matthew E.,  Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato,  Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 |issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>==
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
|-


===<u>Penicillin-Susceptible Strep Viridans and Other Nonenterococcal Streptococci</u>===


====Penicillin G====
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
*If Minimum inhibitory concentration [MIC] <0.2 µg/ml.
|-
*Dose: 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks.
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
|-


====Penicillin G + Gentamicin====
*Dose: Penicillin G, 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks plus gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).


====Ceftriaxone====
|}
*Dose: 2 g I.V. daily as a single dose for 2 weeks.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 17:09, 15 January 2014

Medical Therapy

Pharmacotherapy

Community-Acquired Meningitis

Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
Preferred Regimen
Adult:Aqueous crystalline penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks
Pediatrics:Aqueous crystalline penicillin G sodium 300 000 U/24 h IV in 4–6 equally divided doses X 4 Wks
OR
Adult:Ceftriaxone 2 g/24 h IV/IM in 1 dose
Pediatrics:Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
AND
Adult:Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Pediatrics: Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses X 2 Wks
Relatively Penicillin-Resistant Streptococci, MIC > 0.5 µg/ml, consider Enterococcal regimen
Preferred Regimen
Adult:Aqueous crystalline penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks
AND
Adult:Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Unable to tolerate Aqueous crystalline penicillin G sodium or Ceftriaxone
Preferred Regimen
Adult: Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low
Pediatrics: Vancomycin 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks


Newborn, Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
AND
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
AND
Gentamicin 2.5 mg/kg IV q12h
Newborn, Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Infant and Children
Preferred Regimen
Vancomycin 15 mg/kg IV q6h
to achieve serum trough concentrations of 15–20 μg/mL
AND
Cefotaxime 225—300 mg/kg/day IV q6–8h
OR
Ceftriaxone 80—100 mg/kg/day IV q12–24h



Adult, Age <50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
to achieve serum trough concentrations of 15–20 μg/mL
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Adult, Age >50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
AND
Ampicillin 2 g IV q4h
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Immunocompromised
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
AND
Ampicillin 2 g IV q4h
AND
Cefepime 2 g IV q8h
OR
Meropenem2 g IV q8h
Recurrent
Preferred Regimen
Vancomycin 30—60 mg/kg/day IV q8–12h
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h

Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenesis also suspected.

Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1]

Empiric Treatment

  • Do not wait for the results of the CT scan and the lumbar puncture; empiric treatment should be started as soon as possible.
  • Blood cultures should be drawn before starting the antibiotic therapy, and then the antibiotic treatment should be changed once the blood culture results are out.
  • Empiric antibiotic treatment should be started within 30 minutes after the patient presentation.
  • In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days.
    • The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment.
Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
AND
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
AND
Gentamicin 2.5 mg/kg IV q12h


Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
AND
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
AND
Gentamicin 2.5 mg/kg IV q12h
Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Age 1—23 Months
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin 2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h

References

  1. van de Beek, D.; Brouwer, MC.; Thwaites, GE.; Tunkel, AR. (2012). "Advances in treatment of bacterial meningitis". Lancet. 380 (9854): 1693–702. doi:10.1016/S0140-6736(12)61186-6. PMID 23141618. Unknown parameter |month= ignored (help)